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Abstract 
The effect of tumor necrosis factor on the oxidative modification of LDL by U937 human monocytes or murine endothelial cells was studied by 
determination of the lipid peroxidation product content and the electrophoretic mobility of the particle. In the range of concentrations from 2.5 to 
10 @ml, the cytokine induced a dose-dependent increase in cellular-induced oxidation of LDL. This effect was accompanied by a stimulation of 
LDL degradation by 5774 macrophage-like cells. Concurrently, the TNF-treated cells secreted superoxide anion with a higher rate. Since LDL 
oxidation is believed to be an inportant feature m the formation of the atherosclerotic plaque, the described effects of TNF might be of importance 
in long-term exposure to this cytokine during inflammation. 
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1. Introduction 
Tumor necrosis factor 01 (TNF/cachectin) is a mon- 
ocyte/macrophage-derived cytokine, first identified by its 
antitumor activity in mice [ 11. Besides its cytotoxic/cyto- 
static activity towards transformed cells in vitro [2,3], 
TNF exhibits other biological activities on untrans- 
formed cells. On monocytes/macrophages. TNF exerts a 
powerful function on activation and differentiation [4,5], 
leading to a parasiticidal and bactericidal action. On 
endothelial cells, TNF induces the release of hematopoi- 
etic growth factors [6] and the secretion of interleukins 
[7,8]. 
Low density lipoprotein (LDL) is the major choles- 
terol carrier in plasma, and its oxidative modification by 
cultured cells such as monocytes [9] or endothelial cells 
[lo] leads to a form which is no longer recognized by the 
Apo B/E receptor of fibroblasts, but avidly taken up by 
macrophages via the scavenger receptor pathway [ 11,121. 
This phenomenon is at the origin of cholesteryl-ester 
accumulation by macrophages and of their subsequent 
transformation to foam cells located in the atheroscle- 
rotic plaque. It is currently believed that oxidative mod- 
ification of LDL plays an important role in the initiation 
and progression of atherosclerosis (for review see [ 131). 
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In the present work, we investigated the effects of TNF 
on the oxidative modification of LDL by monocytes and 
endothelial cells, as studied by measurement of lipid per- 
oxidation products, and determination of the electro- 
phoretic mobility of the LDL particle. It was demon- 
strated that the cytokine enhanced LDL modification 
and superoxide secretion by the two cell types. 
2. Materials and methods 
2.1. Materzals 
Human recombinant TNF was from Boehringer Mannhelm, 
Mannheim, Germany. Horse heart cytochrome c and horse radish 
superoxide dismutase were purchased from Sigma, St Louis, MO, USA. 
Cell culture medium and fetal calf serum were from Gibco, Grand 
Island, NY, USA. The U937 monocyte-like human cell line and the 
5774 murine macrophage-like cells were from The American Type Cul- 
ture Collection, Rockville, Maryland, USA. Na-lz51 (13-17 Ci/mg) was 
purchased from Amersham, Buckinghamshire, UK. 
2.2. LDL preparation and labelling 
LDL (d 1.0241.050) was prepared from human normal serum by 
sequential ultracentrifugation according to Have1 et al. [14], and dia- 
lysed against 0.005 M Tris, 0.05 M NaCI, 0.02% EDTA pH 7.4 for 
conservation. Prior to oxidation, EDTA was removed by dialysis dur- 
ing 24 h, and LDL, stored at 4°C were utilized within 2 days. The 
TBARS value of native LDL was 4-5 nmol MDA/mg LDL protein. 
‘Z51-labelling of LDL was performed as described by Bilheimer et al. 
[15]. The specific activity was about 250 cprn/ng. 
2.3. Cell culture 
The U937 monocyte-like cells (16) were maintained in suspension in 
RPM1 medium supplemented with 10% inactivated fetal calf serum. 
Monolayers were obtained when cells were shifted to Ham’s FlO me- 
dium containing lo-’ M 12-O-tetradecanoyl phorbol 13-acetate. Exper- 
iments were performed with confluent cultures. 
All rights reserved. 
C. Mariere et al. IFEBS Letters 338 (1994) 4346 
la 
250 7) 
0 2 4 6 6 10 
Concentration ( ng / ml ) 
lb 
0 2 4 6 8 10 
Concentration ( ng / ml ) 
Fig. 1. Effect of TNF on LDL oxidation studled by TBARS production (a), or relative electrophoretic mobility (b). Cells were pretreated for 24 h 
with TNF before addition of 50 &ml LDL protein for a further 24 h incubation time. Means of 6 experimental values + S.D. 100%: 48 t 4 nmol 
equivalent malondialdehyde/mg LDL protein. ICI: U937 monocyte cells; A: endothelial cells. 
The murine endothelial cell line UNA was a gift from Professor J.D. 
Chapman, The Fox Chase Cancer Center, Philadelphia, PA, USA. This 
cell line was characterized by the presence of von Willebrand’s factor 
Cells were maintained in Ham’s FlO medium supplemented with 10% 
fetal calf serum. LDL oxidation was performed on confluent cells. 
The 5774 macrophage cell line was maintained in suspension in 
RPM1 1640 medium supplemented with 10% heat-inactivated fetal calf 
serum. For the determination of LDL degradation, cells were seeded 
in 3.5 cm Petri dishes (1.5 x lo6 cells/dish). All experiments were per- 
formed on confluent cultures (about 3 x lo6 cells/dish). 
2 4. LDL oxrdation 
Cells in 12-well ulates were Dretreated for 24 h with TNF in medium 
supplemented witi 0.1% boviie serum albumin before introduction of 
50 pg LDL protein/ml for a further 24 h incubation time. The lipid 
peroxidation products (thiobarbituric acid reactive substances: 
TBARS) were measured by the fluorometric assay of Yagi [17]. Results 
are expressed in nmol equivalent malondialdehyde/mg LDL protein, 
using malondialdehyde from tetramethoxypropane as standard, and 
calculated as % of control. The modification of the negative net charge 
of LDL was assessed by agarose gel elctrophoresis at pH 8.6 using a 
Ciba Corning system. 
2.5. LDL degradatron by J774 macrophage-like cells 
Oxidation of [‘251]-LDL by cells in the presence of TNF was first 
carried out with 20 pg/ml LDL as previously described. The medium 
was then transferred to 5774 cells. LDL degradation was determined 
after 6 h as described [18], and expressed in ng LDL degraded/mg 
cellular protein. Blank values from parallel incubations without cells 
were also determined. 
2.6. Secretion of superoxide amon by ceils 
Cells were treated during 48 h with TNF in medium supplemented 
with 0.5% bovine serum albumin. Cells were then incubated for 1 h in 
Dulbecco modified mmimum essential medium devoid of phenol red. 
in the presence of 2.10-’ M cytochrome c. Superoxide anion release was 
calculated from the difference of absorbance at 550 nm in the absence 
and presence of superoxide dismutase 100 pg/ml, using a molar extinc- 
tion coefficient of Zl/mM/cm. 
Each experiment was performed at least 2 times in duplicate. Statis- 
tical analysis was performed by the Student’s t-test. 
3. Results 
The effect of TNF on LDL oxidative modification by 
monocytes and endothelial cells was first investigated by 
determination of the lipid peroxidation product 
(TBARS) content and of the electrophoretic mobility of 
the particle. As it can be seen in Fig. la, at concentra- 
tions ranging from 2.5 to 5 ng/ml, TNF increased in a 
dose-dependent manner the TBARS content and the 
electrophoretic mobility of LDL exposed to either mon- 
ocytes or endothelial cells. The U937 monocyte cell line 
was more sensitive to the action of TNF, in terms of 
TBARS production, than UNA endothelial cells. At 10 
ng/ml, the cytokine induced a 2- and 1.5-fold increase in 
TBARS content of LDL modified by monocytes and 
endothelial cells, respectively. Concomitantly, the rela- 
tive electrophoretic mobility was increased in a parallel 
manner in both cell types (Figs. lb and 2). Furthermore, 
conjugated dienes determination by absorption at 234 
nm also confirmed the effect of TNF: at 10 @ml, an 
increase of 40-50% and 15-25% was observed for mon- 
ocytes and endothelial cells, respectively. 
Table 1 
Degradation by 5774 macrophages of [“‘I]LDL oxidized by monocytes 
or endothelial cells treated with TNF 
Addition [lz5]LDL degradation (ng/mg protein) 
Without cells or Cu” 137f 11 
Monocytes Endothelial cells 
None 436 f 37 574 f 42 
TNF 2.5 @ml 532 f 42* 644+63 
TNF 5 @ml 574 f 43** 679 f 54* 
TNF 10 &ml 603 f 61*** 709 + 67** 
Oxidation of [“‘I]LDL (20 pg/ml) by monocytes and endothelial cells 
was carried out as described in Fig. 1 legend. The medium was then 
transferred to 5774 macrophages for determination of LDL degrada- 
tion after 6 h incubation at 37°C. Results are expressed in ng LDL 
degraded/mg cellular protem. Means of 4 experimental values f S.D. 
*P < 0.05; **P < 0.01; ***P c 0.001 by the Student’s t-test. 
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Fig. 2. Effect of TNF on LDL oxidation by monocytes (a) or endothelial cells (b), studied by electrophoretic mobility. LDL oxidation was performed 
as described in the legend of Fig. 1. Lane 1, native LDL; lane 2, oxidized LDL in the absence of TNF; Lane 3, oxidized LDL in the presence of 
5 ng/ml TNF; lane 4, oxidized LDL in the presence of 10 ng/ml TNF. 
Since it is well known that LDL oxidation leads to a 
form rapidly taken up and degraded by macrophages, 
the action of TNF on cell-induced modification of LDL 
was also assessed by the subsequent step of LDL degra- 
dation by macrophages. From data given in Tabel 1, it 
can be noted that LDL degradation was approximately 
3-fold increased after cellular modification by non- 
treated cells. In addition, when the oxidation was con- 
ducted with TNF-treated cells, the LDL degradation was 
enhanced in a dose-dependent manner. The effect of 
TNF was again more marked with monocyte-like cells: 
at 10 @ml, TNF enhanced by 55% and 30% the LDL 
degradation after oxidation by monocytes or endothelial 
cells, respectively. These results are in close accordance 
with those presented in Fig la, concerning the TBARS 
production during LDL oxidation. 
In the next experiment, we tested whether the stimula- 
tion of LDL modification by TNF was related to a par- 
allel increase in superoxide anion release by cells. It can 
be concluded from the data presented in Table 2 that the 
secretion of superoxide anion was enhanced by TNF. At 
10 &ml, the cytokine induced a 1.5- and 1.3-fold in- 
crease in superoxide production by monocytes and endo- 
thelial cells, respectively. 
4. Discussion 
The cytokine TNF significantly stimulated LDL oxi- 
dative modification by monocytes or endothelial cells. 
This effect was accompanied by enhanced degradation 
of the LDL particle by macrophages. It should be noted 
that when LDL oxidation was conducted using copper 
ions instead of cultured cells, no effect of the cytokine 
could be evidenced (results not shown). This indicates 
that most probably TNF did not act on the LDL particle 
itself, but rather on the cellular mechanisms involved in 
LDL oxidative modification. In this regard, the differ- 
ence in sensitivity to TNF between the two studied cell 
types might be due to the different mechanisms whereby 
cultured cells promote LDL oxidative modification. It 
has been suggested that the ability of a given cell type to 
oxidize LDL was correlated to the rate of superoxide 
anion secretion [19]. The role of superoxide anion in the 
initiation of LDL oxidation was further evidenced by the 
fact that the enzyme superoxide dismutase can inhibit 
LDL modification by monocytes/macrophages [20,21]. 
However, in the case of human endothelial cells, super- 
oxide dismutase can only partially prevent LDL oxida- 
tion [19]. In our system, superoxide dismutase partially 
blocked LDL modification by cells by approximately 
20-25% (data not shown). Furthermore, even in the pres- 
ence of the enzyme, the stimulatory effect of TNF was 
Table 2 
Effect of TNF on superoxide anion release by monocytes and endothe- 
lial cells 
Addition Superoxide anion release 
(nmol/h/mg protein) 
Monocytes Endothelial cells 
None 166 f 17 134 + 12 
TNF 2.5 ng/ml 197 + 16 147 + 11 
TNF 5 ng/ml 209 f 18* 172 f 13* 
TNF 10 @ml 252 f 21** 199 f 18** 
Monocytes or endothelial cells were treated with TNF during 48 h in 
medium supplemented with 0.1% bovine serum albumin before deter- 
mination of the superoxide anion release. Means of 4 experimental 
values ? S.D. *P < 0.05; **P < 0.01 by the Student’s t-test. 
46 
still observed, thus indicating that TNF also acts 
through other mechanisms distinct from superoxide 
anion secretion. It has been reported that LDL modifica- 
tion by endothelial cells also involves a superoxide-inde- 
pendent pathway, the lipoxygenase pathway [22]. In this 
regard, the hypothesis of a positive regulation of the 
lipoxygenase activity by TNF might be raised. It is of 
interest hat TNF has been demonstrated to activate the 
synthesis of cyclooxygenase [23], another enzyme in- 
volved in the metabolism of polyunsaturated fatty acids. 
Our studies also showed that in the same range of 
concentrations, TNF stimulated superoxide anion re- 
lease by the studied cells. This result is in accordance 
with the well known effect of the cytokine on monocytesl 
macrophages activation and differentiation. The stimu- 
latory action of TNF on the release of active oxygen 
species and of reactive nitrogen has been reported [4,5]. 
In addition, it was demonstrated that TNF is a powerful 
inducer of hydroxyl radical production [24] or superox- 
ide anion secretion [25]. This effect is currently believed 
to be responsible for the cytotoxic effect of TNF on 
cancer cells [26]. However, it must be stressed that under 
our experimental conditions, no cytotoxicity was noticed 
in TNF-treated cells, as assessed by cellular adherence 
and thymidine incorporation (data not shown). 
Previous studies pointed at the multiple effects of TNF 
on endothelial cell functions. In endothelial cells, TNF 
induces the expression of mononuclear leukocyte adhe- 
sion molecule [27]. The cytokine also strongly promotes 
tissue factor-like procoagulant activity [28] and sup- 
presses endothelial cell surface anticoagulant activity 
[29]. A chemotactic action of TNF towards monocytes 
was already reported [30]. It should be noted that the 
concentrations of TNF utilized in the current studies are 
within the physiologic range [31]. It can thus be sug- 
gested that TNF might exert a non-negligible effect on 
the initiation and progression of the atherosclerotic 
plaque. 
The production of TNF by activated monocytes, mac- 
rophages and T lymphocytes has an evident protective 
role against bacterial and parasitic infections. However, 
long-term exposure to this cytokine might induce some 
harmful action rising from the numerous side effects of 
TNF on endothelial cell functions, especially concerning 
the formation of atheromatous lesions. 
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